Skip to main content

Bio-Rad s Q3 Sales Increase 9.4 Percent as R&D Spending, Profits Climb

NEW YORK, Nov. 4 (GenomeWeb News) - Bio-Rad Laboratories yesterday reported a 9.4-percent increase in net sales for the third quarter, which it attributed to strong sales in protein-expression analysis, process chromatography, diabetes monitoring, blood virus screening, and quality control products.


Net sales for the quarter ended Sept. 30 increased to $283.2 million from $258.8 million for the third quarter last year.


R&D spending in the quarter increased 8 percent to $28.7 million from $26.6 million during the same period last year.


Third quarter income from continuing operations was up 158 percent to $16.2 million, or $.62 cents per share, from $6.2 million, or $.24 per share, during the same period last year.


As of Sept. 30, BioRad had $244 million in cash and cash equivalents.


BioRad said that sales in its life science business could be hurt by a lawsuit against Applera and Roche that prevents the company from selling its MJ Research line of thermal cycling products acquired in August 2004.


Sales in life sciences could be reduced by as much as $10 million to $15 million during the fourth quarter due to a lawsuit, and pre-tax operating profit could be reduced by $8 million to $10 million compared to prior expectations, the company said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.